$4.00
0.25% today
Nasdaq, Feb 28, 05:15 pm CET
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Voyager Therapeutics, Inc. Stock price

$4.01
-1.62 28.77% 1M
-2.62 39.52% 6M
-1.66 29.28% YTD
-4.90 54.99% 1Y
+0.04 1.01% 3Y
-6.59 62.17% 5Y
-13.74 77.41% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.12 2.91%
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Key metrics

Market capitalization $219.05m
Enterprise Value $-80.96m
P/E (TTM) P/E ratio 5.56
EV/FCF (TTM) EV/FCF 2.82
EV/Sales (TTM) EV/Sales -0.49
P/S ratio (TTM) P/S ratio 1.34
P/B ratio (TTM) P/B ratio 0.66
Revenue growth (TTM) Revenue growth 3.40%
Revenue (TTM) Revenue $163.78m
EBIT (operating result TTM) EBIT $9.08m
Free Cash Flow (TTM) Free Cash Flow $-28.66m
Cash position $345.36m
EPS (TTM) EPS $0.72
P/E forward negative
P/S forward 2.43
EV/Sales forward negative
Short interest 5.69%
Show more

Is Voyager Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Voyager Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Voyager Therapeutics, Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Voyager Therapeutics, Inc. forecast:

Buy
100%

Financial data from Voyager Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
164 164
3% 3%
100%
- Direct Costs 5.06 5.06
28% 28%
3%
159 159
3% 3%
97%
- Selling and Administrative Expenses 32 32
7% 7%
20%
- Research and Development Expense 112 112
46% 46%
69%
14 14
70% 70%
9%
- Depreciation and Amortization 5.06 5.06
28% 28%
3%
EBIT (Operating Income) EBIT 9.08 9.08
79% 79%
6%
Net Profit 26 26
51% 51%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Voyager Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Voyager Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, in Boston, including a fireside chat at 1:50 p.m.
Neutral
GlobeNewsWire
4 days ago
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR) on behalf of Voyager stockholders. Our investigation concerns whether Voyager has violated the federal securities laws and/or engaged in other unlawful busines...
Neutral
GlobeNewsWire
9 days ago
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR). The investigation concerns whether Voyager and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
More Voyager Therapeutics, Inc. News

Company Profile

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alfred Sandrock
Employees 162
Founded 2013
Website www.voyagertherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today